Previous controlled trials comparing the combination therapy with oral hypoglycemic agents (SU plus Metformin) and insulin therapy in patients with poorly controlled type 2 diabetes are sparse [14]–[16], and among these studies, reports about a peakless, long-acting insulin analog are executive. Here, INS is linked to type 2 diabetes mellitus.